Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02801097 · ClinicalTrials.gov registry record · Phase 1
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
A Phase 1 study, sponsored by EpicentRx.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02801097 is a Phase 1 study that was terminated before completion, run by EpicentRx. The registered enrollment target is 28 participants.
The verdict
NCT02801097, a Phase 1 study, was terminated before completion, sponsored by EpicentRx.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical activity of RRx-001 administered in combination with irinotecan. RRx-001 is associated with resensitization to irinotecan in tumors that are previously refractory. This effect has been attributed to the ability of RRx-001 to restore the expression of aberrantly silenced genes, thus re-establishing pathway functions. However, resensitization may have more than one mechanism, among them Pgp pump inhibition and vascular modulation, leading to improved penetration of standard chemotherapy.
Interventions
- DRUG Irinotecan
- DRUG RRx-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2019-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02801097
The ClinicalTrials.gov registry entry for NCT02801097 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EpicentRx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irinotecan is the first listed.
NCT02801097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02801097 about?
NCT02801097 is a clinical study titled "RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)". This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical activity of RRx-001 administered in combination with irinotecan. RRx-001 is associated with resensitization to irinotecan in tumors that are previously refractory. This effect has been attributed to the ability...
What is the current status of trial NCT02801097?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-08-30. Estimated completion is 2019-12-09.
What interventions are being tested in trial NCT02801097?
The interventions under investigation include: Irinotecan (DRUG), RRx-001 (DRUG).
Who is sponsoring clinical trial NCT02801097?
This trial is sponsored by EpicentRx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.